CA2120743C Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives Disclosed are acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives and a pharmaceutical composition comprising said purine and pyrimidine derivatives. The compounds are useful in the treatment of viral infections, especially those caused by human immunodeficiency virus (HIV).
CA2163175C Anti-viral aromatic o-alkylated oximes, ethers and thioethers Compounds of the formula (see formula I) wherein Q is (see formula II) or -XR' ; X is oxygen or sulphur;  R1 is hydrogen, halogen, C1-C4 alkyl or C1-C4 alkoxy; R2 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C4 alkenyloxy, C3-C4 alkynyloxy, mono-, di- or tri-halomethyl, trifuluoromethoxy, C1-C4 alkylthio, C3-C4 branched alkylthio, nitro, or cyano;  R3 is hydrogen or C1-C4 alkyl;  R 4 is C3-C6 alkenyl, C3-C6 alkynyl, C1-C8 haloalkyl, C1-C8 alkoxyalkyl, C1-C8 alkylthioalkyl, C1-C8 hydroxyalkyl, C1-C8 acyloxyalkyl, C1-C8 aroyloxyalkyl, C1-C8 carboxyalkyl, C1-C8 alkylcarboxyalkyl, C6-C12 arylcarboxyalkyl, C1-C8 aminoalkyl, C1-C8 alkylaminoalkyl, C1-C8 dialkylaminoalkyl, C1-C8 trialkylsilylalkyl, wherein each of the aforementioned alkyl moieties may be straight-chain or branched; C3-C8 cycloalkyl, C1-C6 alkylphenyl, C7-C12 arylalkyl, C7-C12 alkarylalkyl, or heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl, tetrahydropyranyl or tetrahydrofuranyl;  R' is C1-C8 haloalkyl, C1-C8 alkoxyalkyl, C1-C8 alkylthioalkyl, C1-C8 hydroxyalkyl, C1-C8 acyloxyalkyl, C1-C8 aroyloxyalkyl, C1-C8 aminoalkyl, C1-C8 alkylaminoalkyl, C1-C8 dialkylaminoalkyl, C1-C8 trialkylsilylalkyl, wherein each of the aforementioned alkyl moieties may be straight-chain or branched; C1-C6 alkylphenyl, C7-C12 arylalkyl, C7-C12 alkarylalkyl, or heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl, tetrahydropyranyl or tetrahydrofuranyl;  R5 is hydrogen, halo, methyl, mono-, di- or tri-halomethyl; and R6 is an aliphatic or cyclic side chain as defined herein.  These compounds are useful for inhibiting the growth or replication of retroviruses such as HIV.
CA2318184C Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative as selective endothelin antagonists The present invention relates to a cyclopentenopyridine derivative represented by general formula [I] or a pharmaceutically acceptable salt thereof: (see formula I) wherein Ar is a phenyl group or the like, R1 is a mono-or di-C1-C6 alkylamino group or the like, and R2 is a hydroxyl group or the like, a process for its production and its use as endothelin antagonist.
CN100581544C Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction An injectable pharmaceutical composition for treatment of erectile dysfunction. The composition includes prostaglandin E-1, and optionally further includes levsin and/or additional vasodilators such as diltiazem HC1, veparamill, chlorpromazine, d,L-hyoscyamine, and 6,7-dimethoxy-1-veratrylisoquinoline HC1. The composition is effective for long-term restoration of normal erectile function to a patient having erectile dysfunction. The ability to reverse erectile dysfunction may be further enhanced by the inclusion of vitamin B-6, B12, folic acid, and/or TPA. Also disclosed are methods for treatment and reversal of erectile dysfunction by injecting the pharmaceutical composition into the penis, either by subcutaneous or intracavernosal injection.
CN101054403A Novel antibiotic Chemomycin A, B, C, D and preparation method thereof The present invention relates to a group of novel compound Chemomicin B,C,D and its preparation method, pharmaceutical composition containing Chemomicin B,C,D as active ingredients and its uses of Chemomicin B,C,D in preparing antineoplastic drug. Chemomicin B,C,D is Angucyclinone antibiotic separated from Nocardia Mediterranei Var.Kanglensis 1747-64 culture. In vitro activity test prove Chemomicin B,C,D has strong suppressing activity for human oesophagus cancer cell KYSE150 and has good development prospect as a novel antineoplastic drug.
